<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）内部人士 Peter Heerma 于 12 月 24 日（星期三）出售了 4,980 股 Travere Therapeutics 股票。股票以平均价格 40.00 美元出售，总交易额为 199,200.00 美元。出售后，该内部人士持有公司 113,013 股股票，估值约为 4,520,520 美元。此次交易使其持股比例减少了 4.22%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家低调的医疗保健公司</li>
</ul>
<p>Peter Heerma 最近还进行了以下交易：</p>
<ul>
<li>在 10 月 31 日（星期五），Peter Heerma 出售了 5,591 股 Travere Therapeutics 股票。股票以平均价格 35.00 美元出售，总交易额为 195,685.00 美元。</li>
<li>在 10 月 28 日（星期二），Peter Heerma 出售了 2,662 股 Travere Therapeutics 股票。股票以平均价格 30.00 美元出售，总交易额为 79,860.00 美元。</li>
</ul>
<h2>Travere Therapeutics 价格表现</h2>
<p>在周一的午盘交易中，纳斯达克 TVTX 的股票下跌 0.76 美元，达到 38.88 美元。该公司交易了 1,348,814 股，较其平均交易量 1,736,032 股有所减少。Travere Therapeutics, Inc.的 52 周低点为 12.91 美元，52 周高点为 42.13 美元。公司的 50 日移动平均价格为 34.36 美元，200 日移动平均价格为 24.61 美元。该股票的市值为 34.8 亿美元，市盈率为-36.68，贝塔值为 0.89。公司流动比率为 2.71，当前比率为 2.75，债务与股本比率为 4.23。</p>
<ul>
<li>Travere Therapeutics 在鼓舞人心的数据发布后仍在上涨</li>
</ul>
<p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最近于 10 月 30 日（星期四）发布了其财报。公司报告本季度每股收益为 0.28 美元，超出分析师一致预期的-0.31 美元，超出幅度为 0.59 美元。Travere Therapeutics 的股本回报率为-178.68%，净利润率为-20.32%。该业务本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司每股收益为-0.70 美元。公司的收入同比增长 162.1%。卖方分析师预测，Travere Therapeutics, Inc.在本财年将发布-1.4 的每股收益。</p>
<h2>分析师评级上调与下调</h2>
<p>多位分析师最近对 TVTX 股票发表了看法。Stifel Nicolaus 在 9 月 12 日（星期五）的研究报告中将 Travere Therapeutics 的目标价格从 20.00 美元上调至 25.00 美元，并给予该股票 “持有” 评级。Wall Street Zen 在 12 月 13 日（星期六）的研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。Zacks Research 在 11 月 12 日（星期三）的报告中将 Travere Therapeutics 的评级从 “强力买入” 下调至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究报告中重申了 “买入” 评级，并对 Travere Therapeutics 的股票设定了 47.00 美元的目标价。最后，Jefferies Financial Group 在 9 月 10 日（星期三）的研究报告中对 Travere Therapeutics 的股票设定了 35.00 美元的目标价。十三位研究分析师对该股票给予了 “买入” 评级，三位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat，Travere Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 38.71 美元。</p>
<p><strong>阅读我们最新的 TVTX 股票报告</strong></p>
<h2>机构资金流入与流出</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Northern Trust Corp 在第一季度将其在 Travere Therapeutics 的股份增加了 7.2%。Northern Trust Corp 目前拥有 808,687 股公司股票，价值 14,492,000 美元，在此期间又购买了 54,292 股。汇丰控股（Hsbc Holdings PLC）在第一季度将其在 Travere Therapeutics 的持仓增加了 10.4%。汇丰控股目前拥有 30,737 股公司股票，价值 542,000 美元，在此期间又收购了 2,902 股。大都会人寿投资管理公司（MetLife Investment Management LLC）在第一季度将其在 Travere Therapeutics 的持仓增加了 10.2%。大都会人寿投资管理公司目前拥有 49,288 股公司股票，价值 883,000 美元，在此期间又收购了 4,577 股。Corebridge Financial Inc.在第一季度将其在 Travere Therapeutics 的股份增加了 9.7%。Corebridge Financial Inc.目前拥有 41,211 股公司股票，价值 739,000 美元，在上个季度又收购了 3,646 股。最后，Ieq Capital LLC 在第一季度将其在 Travere Therapeutics 的股份增加了 60.6%。Ieq Capital LLC 目前拥有 33,323 股公司股票，价值 597,000 美元，在上个季度又收购了 12,574 股。</p>
<h2>Travere Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的治疗方案。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的情况中的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
<p>公司的主要产品是 sparsentan，这是一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Travere Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 人工智能奇迹股票” 即将腾飞</li>
<li>退休时 $1M 能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>如何捕捉 Starlink IPO 热潮的一部分</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Travere Therapeutics 吗？</h2>
<p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>Travere Therapeutics 的内部人士 Peter Heerma 以每股 40.00 美元的价格出售了 4,980 股，总计 199,200 美元，减少了 4.22% 的持股，现持有 113,013 股，估值约为 452 万美元。此交易已向 SEC 披露。该公司的股票目前交易价格为 38.88 美元，市值为 34.8 亿美元，市盈率为 -36.68。最近的财报显示，收入同比大幅增长 162.1%，每股收益为 0.28 美元，超出预期。分析师对该股票的评级不一，普遍目标价为 38.71 美元</p>

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 4,980 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total transaction of $199,200.00. Following the sale, the insider owned 113,013 shares of the company's stock, valued at approximately $4,520,520. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）内部人士 Peter Heerma 于 12 月 24 日（星期三）出售了 4,980 股 Travere Therapeutics 股票。股票以平均价格 40.00 美元出售，总交易额为 199,200.00 美元。出售后，该内部人士持有公司 113,013 股股票，估值约为 4,520,520 美元。此次交易使其持股比例减少了 4.22%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家低调的医疗保健公司</li>
</ul>
</div><p>Peter Heerma also recently made the following trade(s):</p>
<div class="lb-trans"><p>Peter Heerma 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, October 31st, Peter Heerma sold 5,591 shares of Travere Therapeutics stock. The stock was sold at an average price of $35.00, for a total transaction of $195,685.00.</li>
<li>On Tuesday, October 28th, Peter Heerma sold 2,662 shares of Travere Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $79,860.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 10 月 31 日（星期五），Peter Heerma 出售了 5,591 股 Travere Therapeutics 股票。股票以平均价格 35.00 美元出售，总交易额为 195,685.00 美元。</li>
<li>在 10 月 28 日（星期二），Peter Heerma 出售了 2,662 股 Travere Therapeutics 股票。股票以平均价格 30.00 美元出售，总交易额为 79,860.00 美元。</li>
</ul>
</div><h2>Travere Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ TVTX traded down $0.76 during mid-day trading on Monday, reaching $38.88. 1,348,814 shares of the company were exchanged, compared to its average volume of 1,736,032. Travere Therapeutics, Inc. has a 52 week low of $12.91 and a 52 week high of $42.13. The company's 50 day moving average price is $34.36 and its 200 day moving average price is $24.61. The stock has a market capitalization of $3.48 billion, a PE ratio of -36.68 and a beta of 0.89. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23.</p>
<div class="lb-trans"><p>在周一的午盘交易中，纳斯达克 TVTX 的股票下跌 0.76 美元，达到 38.88 美元。该公司交易了 1,348,814 股，较其平均交易量 1,736,032 股有所减少。Travere Therapeutics, Inc.的 52 周低点为 12.91 美元，52 周高点为 42.13 美元。公司的 50 日移动平均价格为 34.36 美元，200 日移动平均价格为 24.61 美元。该股票的市值为 34.8 亿美元，市盈率为-36.68，贝塔值为 0.89。公司流动比率为 2.71，当前比率为 2.75，债务与股本比率为 4.23。</p>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的数据发布后仍在上涨</li>
</ul>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The business had revenue of $164.86 million for the quarter, compared to analysts' expectations of $106.09 million. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. The firm's revenue was up 162.1% on a year-over-year basis. Sell-side analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最近于 10 月 30 日（星期四）发布了其财报。公司报告本季度每股收益为 0.28 美元，超出分析师一致预期的-0.31 美元，超出幅度为 0.59 美元。Travere Therapeutics 的股本回报率为-178.68%，净利润率为-20.32%。该业务本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司每股收益为-0.70 美元。公司的收入同比增长 162.1%。卖方分析师预测，Travere Therapeutics, Inc.在本财年将发布-1.4 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of analysts recently weighed in on TVTX shares. Stifel Nicolaus boosted their target price on Travere Therapeutics from $20.00 to $25.00 and gave the stock a &#34;hold&#34; rating in a research report on Friday, September 12th. Wall Street Zen raised shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, December 13th. Zacks Research lowered shares of Travere Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, November 12th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Friday, November 28th. Finally, Jefferies Financial Group set a $35.00 target price on shares of Travere Therapeutics in a research report on Wednesday, September 10th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $38.71.</p>
<div class="lb-trans"><p>多位分析师最近对 TVTX 股票发表了看法。Stifel Nicolaus 在 9 月 12 日（星期五）的研究报告中将 Travere Therapeutics 的目标价格从 20.00 美元上调至 25.00 美元，并给予该股票 “持有” 评级。Wall Street Zen 在 12 月 13 日（星期六）的研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。Zacks Research 在 11 月 12 日（星期三）的报告中将 Travere Therapeutics 的评级从 “强力买入” 下调至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究报告中重申了 “买入” 评级，并对 Travere Therapeutics 的股票设定了 47.00 美元的目标价。最后，Jefferies Financial Group 在 9 月 10 日（星期三）的研究报告中对 Travere Therapeutics 的股票设定了 35.00 美元的目标价。十三位研究分析师对该股票给予了 “买入” 评级，三位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat，Travere Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 38.71 美元。</p>
</div><p><strong>Read Our Latest Stock Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 TVTX 股票报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp increased its stake in shares of Travere Therapeutics by 7.2% in the first quarter. Northern Trust Corp now owns 808,687 shares of the company's stock worth $14,492,000 after buying an additional 54,292 shares during the period. Hsbc Holdings PLC increased its position in shares of Travere Therapeutics by 10.4% in the first quarter. Hsbc Holdings PLC now owns 30,737 shares of the company's stock valued at $542,000 after acquiring an additional 2,902 shares during the period. MetLife Investment Management LLC increased its position in shares of Travere Therapeutics by 10.2% in the first quarter. MetLife Investment Management LLC now owns 49,288 shares of the company's stock valued at $883,000 after acquiring an additional 4,577 shares during the period. Corebridge Financial Inc. raised its stake in shares of Travere Therapeutics by 9.7% during the first quarter. Corebridge Financial Inc. now owns 41,211 shares of the company's stock valued at $739,000 after acquiring an additional 3,646 shares during the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Travere Therapeutics by 60.6% during the first quarter. Ieq Capital LLC now owns 33,323 shares of the company's stock valued at $597,000 after acquiring an additional 12,574 shares during the last quarter.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Northern Trust Corp 在第一季度将其在 Travere Therapeutics 的股份增加了 7.2%。Northern Trust Corp 目前拥有 808,687 股公司股票，价值 14,492,000 美元，在此期间又购买了 54,292 股。汇丰控股（Hsbc Holdings PLC）在第一季度将其在 Travere Therapeutics 的持仓增加了 10.4%。汇丰控股目前拥有 30,737 股公司股票，价值 542,000 美元，在此期间又收购了 2,902 股。大都会人寿投资管理公司（MetLife Investment Management LLC）在第一季度将其在 Travere Therapeutics 的持仓增加了 10.2%。大都会人寿投资管理公司目前拥有 49,288 股公司股票，价值 883,000 美元，在此期间又收购了 4,577 股。Corebridge Financial Inc.在第一季度将其在 Travere Therapeutics 的股份增加了 9.7%。Corebridge Financial Inc.目前拥有 41,211 股公司股票，价值 739,000 美元，在上个季度又收购了 3,646 股。最后，Ieq Capital LLC 在第一季度将其在 Travere Therapeutics 的股份增加了 60.6%。Ieq Capital LLC 目前拥有 33,323 股公司股票，价值 597,000 美元，在上个季度又收购了 12,574 股。</p>
</div><h2>Travere Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的治疗方案。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的情况中的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要产品是 sparsentan，这是一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>How to Capture a Slice of the Starlink IPO Buzz</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Travere Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 人工智能奇迹股票” 即将腾飞</li>
<li>退休时 $1M 能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>如何捕捉 Starlink IPO 热潮的一部分</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Travere Therapeutics (NASDAQ:TVTX) 的内部人士 Peter Heerma 出售了 4,980 股股票